NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI) investigators are authors on 11 clinical trial abstracts accepted for presentation during the 2012 San Antonio Breast Cancer Symposium, which takes place Dec. 4-8.
“We are excited to share SCRI’s research efforts with our scientific colleagues at this important breast cancer conference,” SCRI Chief Medical Officer Howard A. Burris III, M.D. said. “The findings are compelling in many cases and demonstrate advances against various breast cancer clinical scenarios our patients face.”
SCRI Senior Investigator, Breast Cancer Research Program, Denise A. Yardley, M.D. serves as lead author on seven of the 11 studies that will be presented at the meeting. Other SCRI principal investigators who co-authored abstracts to be presented include Dr. Burris, Chief Scientific Officer, Dr. John D. Hainsworth and Director of Drug Development Dr. Jeffrey R. Infante. Details are as follows:
| Presentation Title: | SCRI Authors: | Presentation Time: | ||||||||
| Eribulin/cyclophosphamide vs. docetaxel/cyclophosphamide as neoadjuvant therapy in locally advanced HER2-negative breast cancer: a randomized phase II trial of Sarah Cannon Research Institute |
Primary: Yardley |
Exhibit Hall A-B [#OT3-3-08] (Ongoing Trials Poster Session 3, 8th poster in the 3rd category) | ||||||||
| Neoadjuvant sunitinib (S) administered with weekly paclitaxel (P) /carboplatin(C) in patients with locally advanced triple-negative breast cancer (TNBC): preliminary results from a phase I/II trial of Sarah Cannon Research Institute |
Primary: Yardley |
Exhibit Hall A-B [#P1-14-14] (Poster Session 1, 14th poster in the 14th category) | ||||||||
| Sorafenib plus ixabepilone as first-line treatment for patients with HER2-negative metastatic breast cancer: preliminary results of the phase II trial of the Sarah Cannon Research Institute |
Primary: Yardley |
Exhibit Hall A-B [#P5-17-05] (Poster Session 5, 5th poster in the 17th category) | ||||||||
| Panitumumab, gemcitabine and carboplatin in triple-negative metastatic breast cancer: preliminary results of a phase II trial of Sarah Cannon Research Institute |
Primary: Yardley |
Exhibit Hall A-B [#P5-20-10] (Poster Session 5, 10th poster in the 20th category) | ||||||||
| Quantitative measurement of HER2 expression in breast cancers: comparison with “real world” HER2 testing in a multi-center Collaborative Biomarker Study (CBS) and correlation with clinicopathological features |
Primary: Yardley |
Exhibit Hall A-B [#P2-05-06] (Poster Session 2, 6th poster in the 5th category) | ||||||||
| Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer |
Co-Author: Burris |
Exhibit Hall C- P6-04-02 | ||||||||
| A randomized phase II study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: the EMERGE study |
Primary: Yardley |
Exhibit Hall C- P6-10-01 | ||||||||
| A phase II, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer |
Co-Author: Yardley |
Exhibit Halls A-B: P3-12-04 | ||||||||
| Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA |
Co-Author: Burris |
Exhibit Hall C- P6-10-07 | ||||||||
| A phase Ib study of LCL161, an oral inhibitor of apoptosis (IAP) antagonist, in combination with weekly paclitaxel in patients with advanced solid tumors |
Co-Author: Infante |
Exhibit Hall C- P6-11-06 | ||||||||
| Post-hoc safety and tolerability assessment in patients receiving palliative radiation during treatment with eribulin mesylate for metastatic breast cancer |
Primary: Yardley |
Exhibit Hall C- P6−11−14 | ||||||||
About SABCS
The objective of the SABCS is to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant disease, to an international audience of academic and private physicians and researchers. This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals.
About SCRI
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit sarahcannonresearch.com.